Skip to main content
letter
. 2021 Mar 20;35(7):e411–e412. doi: 10.1111/jdv.17170

Figure 1.

Figure 1

Patient, before the pandemic, with a full‐grown hair and no signs of disease activity, using tofacitinib 5 mg BID.